Hasan Jilaihawi, MD, is an Interventional Cardiologist,
and Associate Professor of Medicine and Cardiothoracic Surgery at NYU Langone Medical Center. He also directs the NYU Imaging Corelab and is Co-Director of Transcatheter Valve Therapies. He is heavily involved in all aspects of clinical cardiology, with a special interest in innovative methods of imaging the heart, complex percutaneous coronary intervention and device and patient selection for transcatheter aortic valve replacement (TAVR) and other heart valve therapies. In 2007, he was one of the two doctors who performed the UK's first TAVR procedure and also helped perform the first successful transcatheter pulmonary valve replacement procedure with a self-expanding device in Vietnam in 2011. His international reputation in the field has earned him the prestigious responsibility of running multiple CT corelabs for clinical trials of TAVR and other transcatheter valve therapies in the US, Europe, South America, Japan and China. This included running the CT corelab for China’s first TAVR trial, for which he recently received the People's Republic of China Innovation Award for Contributions to Cardiology.
Dr. Jilaihawi graduated from the University of Edinburgh in 1999 with Honors. He trained in several nations world-wide, including Scotland (Royal Infirmary of Edinburgh), England (Barts and The Royal London Hospital and University Hospitals of Leicester), the USA (Harvard Medical School), France (Clinique Pasteur, Toulouse) and Canada (Montreal Heart Institute). He completed an advanced interventional cardiology fellowship at Cedars-Sinai Medical Center and continued there as Interventional Cardiology faculty for 5 years between 2011 and 2016 before taking his current position. Hasan is fluent in English, French and Arabic. He has authored over 100 publications and several book chapters in his field, as well as being a speaker at numerous international meetings and an active reviewer for several high-profile journals. His research has focused on the use of multi-modality state-of-the-art imaging to guide procedural planning and better understand valvular heart disease and optimally advance its therapies.
This website is optimized for Chrome and Internet Explorer 11.